Eurand N.V.
Olympic Plaza
Fred Roeskestraat 123
Amsterdam,
1076 EE
Netherlands - Map
Phone: 31 20 673 2744
Web Site: http://www.eurand.com
| Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. The company develops these products based on its proprietary customized release technologies used to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; Tastemasking/ODTs technologies to increase patient compliance through more convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technologies to improve drug absorption; and drug conjugation technologies to extend drug half-life and to target specific organs or other biological targets, such as tumors. Its technologies are used for applications in drug products used for various therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition, and respiratory. The company offers EUR-1037, as an over-the-counter sleep-aid; EUR-1025, an oral formulation of ondansetron, an anti-emetic prescribed to prevent nausea and vomiting; and EUR-1073, an enteric coated, controlled release formulation of beclomethasone diproprionate for the treatment of inflammatory bowel disease. It products also include Zentase, also known as EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency, which has completed Phase III clinical trials; Amrix, a sustained release formulation of cyclobenzaprine hydrochloride, used as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions; and products and services to the cystic fibrosis community. The company was formerly known as Eurand B.V. Eurand N.V. was incorporated in 1984 and is based in Amsterdam, the Netherlands. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Gearóid M. Faherty , 49
Chairman and Chief Exec. Officer |
N/A
| N/A | Mr. Mario P. Crovetto , 55
Chief Financial Officer and Principal Accounting Officer |
N/A
| N/A | Mr. John J. Fraher , 43
Chief Commercial Officer |
N/A
| N/A | Ms. Ruth Thieroff-Ekerdt M.D,
Chief Medical Officer |
N/A
| N/A | Dr. Robert Becker M.D.,
Chief Research Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.10% Nasdaq 
0.27%
Profile
